Abstract: A method is disclosed for modifying an oligonucleotide, which method has application to the detection of a polynucleotide analyte. An oligonucleotide is reversibly hybridized with a polynucleotide, for example, a polynucleotide analyte, in the presence of a 5'-nuclease under isothermal conditions. The polynucleotide analyte serves as a recognition element to enable a 5'-nuclease to cleave the oligonucleotide to provide (i) a first fragment that is substantially non-hybridizable to the polynucleotide analyte and (ii) a second fragment that lies 3' of the first fragment (in the intact oligonucleotide) and is substantially hybridizable to the polynucleotide analyte. At least a 100-fold molar excess of the first fragment and/or the second fragment are obtained relative to the molar amount of the polynucleotide analyte. The presence of the first fragment and/or the second fragment is detected, the presence thereof indicating the presence of the polynucleotide analyte.

Abstract: The invention relates to a method for determining the ionic strength and/or the specific weight of aqueous liquids and a reagent for this purpose, the composition of the reagent being such that the color change indicating the ionic strength is essentially directly dependent on the specific weight of the liquid to be determined and not on a pH shift.

Abstract: A method is disclosed for modifying an oligonucleotide, which method has application to the detection of a polynucleotide analyte. An oligonucleotide is reversibly hybridized with a polynucleotide, for example, a polynucleotide analyte, in the presence of a 5'-nuclease under isothermal conditions. The polynucleotide analyte serves as a recognition element to enable a 5'-nuclease to cleave the oligonucleotide to provide (i) a first fragment that is substantially non-hybridizable to the polynucleotide analyte and (ii) a second fragment that lies 3' of the first fragment (in the intact oligonucleotide) and is substantially hybridizable to the polynucleotide analyte. At least a 100-fold molar excess of the first fragment and/or the second fragment are obtained relative to the molar amount of the polynucleotide analyte. The presence of the first fragment and/or the second fragment is detected, the presence thereof indicating the presence of the polynucleotide analyte.

Abstract: A method for determining the concentration of the free fraction of an active compound, present in a biological fluid, in the presence of natural binders, the free and bound fractions of the active compound being in mutual equilibrium, bya) contacting a sample of the fluid with an unlabeled antibody,b) separating the sample from the unlabeled antibody,c) incubating the unlabeled antibody with a labeled substance (tracer) for cross-reaction with the antibody andd) measuring the amount of the tracer which is or is not bound to the antibody and calculating from this the concentration of the free fraction of the active compound,wherein the quantity of the unlabeled antibody and/or its affinity for the active compound are so small that they do not substantially effect the equilibrium between the free and bound fractions of the active compound, and the affinity of the tracer for the antibody is substantially higher or substantially lower than that of the active compound itself, and a test kit suitable for this metho

Abstract: The present invention involves a process for characterizing the glycosylation of glyco-proteins and an in vitro process for determining the bioavailability of glyco-proteins, based on the "hypothetical charge number" (or N) and usable for both endogenic and exogenic glyco-proteins.

Abstract: A method for the detection of a polynucleotide target sequence is described. The method involves the formation of a covalent or non-covalent bonded pair of nucleotide sequences formed in response to a target polynucleotide sequence, adding nucleotide sequence specific binding proteins each capable of binding one member of the pair of nucleotide sequences, and detecting the specific binding proteins complexed to the pair of nucleotide sequences.

Abstract: Method for specifically detecting a coagulation factor V which has an increased stability toward activated protein C in the activated state.

Abstract: The present invention relates to a piezoelectric sensor for use in diagnostic and analytic processes, in particular for the immunochemical detection of diagnostically relevant specific binding partners.

Abstract: A method for the detection of a polynucleotide target sequence is described. The method involves the formation of a covalent or non-covalent bonded pair of nucleotide sequences formed in response to a target polynucleotide sequence, adding nucleotide sequence specific binding proteins each capable of binding one member of the pair of nucleotide sequences, and detecting the specific binding proteins completed to the pair of nucleotide sequences.

Abstract: A method of measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is disclosed. A method of inactivating interfering cross-reactive material in an assay for measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is also disclosed. Compositions wherein cyclosporin is conjugated to an immunogenic carrier or a label, optionally through a linking group, at an alanine nitrogen atom of the cyclic backbone of cyclosporin are also disclosed. Compositions wherein atiocyclosporin is conjugated, optionally through a linking group, to an immunogenic carrier or a label are also disclosed. Where cyclosporin is conjugated to an immunogenic carrier, the conjugates may be used as immunogens for the preparation of antibodies which are capable of recognizing cyclosporin.

Abstract: A method for the determination of soluble fibrin in a body fluid of a species is described, entailing use of a binding partner which is bound to a solid phase, and of a labeled bioaffinity binding partner, for fibrin.

Abstract: The present invention concerns a nuclear inhibitor which specifically inhibits the activity of sequence specific DNA enhancer binding proteins of Human Papilloma Virus (HPV) and the use of this nuclear inhibitor for the production of a medicament for treatment of human cervical cancer.

Abstract: The present invention relates to a method for instrument determination of measured variable L(t) which changes with time, the intention being to determine the maximum value of L(t) in a region with a linear reaction profile, and the time as well as the duration of the reaction time window being variable with the linear region and depending on the nature of the reaction and the reaction conditions. Specifically, the present invention relates to the determination of protein concentrations with the aid of light scatter, which is produced by specific antibodies, in homogeneous solutions. In particular, the invention relates to reactions which take place slowly and have a largely linear profile over a relatively long time, the rate of formation of antigen-antibody complexes in the linear section of the reaction (V.sub.MaxLin) being determined as the measured variable.

Abstract: A process is described for reactivating purified membrane proteins in which a mixture composed of membrane protein, a phospholipid and a detergent is frozen and subsequently thawed.

Abstract: The invention relates to monoclonal antibodies against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), to the preparation and use thereof and to the use of the epitope defined by the antibody for diagnosis and therapy.

Abstract: The present invention relates to a process for the determination of an analyte, in which a sample optionally containing the analyte to be determined is brought into contact with a first receptor R1, which has a binding affinity for the analyte, immobilized on a solid phase, and a receptor R2, which likewise has a binding affinity for the analyte, is added and in which furthermore the resulting immune complexes are brought into contact with a binding factor which has a binding affinity for the analyte and for a receptor R3 immobilized on the same or a second solid phase and in which the amount of the analyte bound to the first solid phase or, if present, to the second solid phase is detected in a suitable manner.

Abstract: The invention relates to a container seal with a sealing body which can be punctured for supplying or removing liquids to or from a container (3) by means of a blunt hollow needle (10), this sealing body consisting at least partially of a highly elastic material in which a cut is made at the puncture point (23) through at least 75% of its thickness. The seal can in this case be designed independently in the form of a stopper or as a small insert plate for a seal.

Abstract: The present invention relates to the identification of Toxoplasma gondii antigens and the preparation thereof by genetic engineering. A cDNA expression gene bank of this parasite was prepared. Recombinant clones which are of diagnostic interest were identified using a high-titer rabbit anti-Toxoplasma gondii serum, and isolated.

Abstract: The present invention relates to a method for the detection and for the determination of enzymatic reactions in urine, wherein certain substances which improve the optical measurability of the enzymatic reaction are added to the reaction.

Abstract: The present invention relates to a method of carrying out an immunoassay in a multiphase system. Particularly, a sample containing an analyte is brought into contact with a receptor A and a tracer. The analyte can either from a complex with the tracer, or counteract the formation of a complex of receptor A and tracer by competing with the tracer for binding to receptor A, or counteract the formation of a complex of receptor A and tracer by competing with receptor A. Receptor B is added and the signal is determined. In this method, receptor A and receptor B are suitably immobilized, ensuring that the tracer either cannot enter into any binding involving the simultaneous participation of receptors A and B or can enter into such a binding to only such a slight extent that it is nevertheless possible to detect and differentiate differing analyte concentrations.